在异形性高氨酸性综合征中的生物作用剂
Ourania Papaioannou1, Fotios Sampsonas1, Panagiota Tsiri1
1Department of Respiratory Medicine, University Hospital of Patras, 26504 Patras, Greece.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
生物药物有效地降低了异常性高乙氨基酸综合征 (HES) 患者的乙氨基酸计数和疾病爆发. 这种治疗为免疫抑制剂提供了安全的替代方案,改善了患者的治疗结果和生活质量.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 过敏氨基酸性综合征 (HES) 是一种罕见的,异质性疾病,其特征是高氨基酸细胞导致器官损伤.
- 目前的治疗目标侧重于减少疾病爆发和乙氨基酸细胞数量,同时尽量减少副作用.
- 异形性HES诊断需要一个彻底的,多学科的方法.
研究的目的:
- 评估用向生物药物治疗的异常性HES患者的临床,实验室和功能结果.
- 评估抗酸性生物制剂在治疗异常性HES时的安全性和有效性.
- 将结果与传统的免疫抑制疗法进行比较.
主要方法:
- 在2019年10月至2023年10月期间接受梅波利祖马布或本拉利祖马布治疗的11名异形性HES患者的回顾性研究.
- 纳入标准:经过彻底调查的异常性HES和用抗酸性生物制剂的治疗.
- 收集的数据包括临床特征,实验室值 (乙酸细胞计数) 和功能参数 (例如FEV1,喘控制).
主要成果:
- 生物疗法显著降低了中位胆固醇细胞数量,从基线时的3000K/μL降至12个月后的50K/μL (p=0.0002).
- 所有8名喘患者都经历了爆发的消失,改善了喘控制 (ACQ < 0.75),以及肺功能改善 (平均 ΔFEV1: 857 mL).
- 在喘患者中观察到口服皮质类固醇使用量减少了82% (p=0.0001),证明了治疗有效性和类固醇节约潜力.
结论:
- 针对性生物制剂在经过全面的诊断工作后,对于异常性HES是安全有效的.
- 这些生物制剂为潜在的有毒免疫抑制剂提供了有希望的替代品.
- 需要更多来自较大的患者登记册的现实数据来证实这些发现.
更多相关视频
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
156
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
156
01:19Antiasthma Drugs: Leukotriene Modifiers
150
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
150
01:17Drugs Used in Lower Respiratory Disorders: Overview
244
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
244
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
85
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
85
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
136
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
136
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97